JBM  Vol.6 No.1 , January 2018
Expression of Skin Barrier Protein Filaggrin in Skin Diseases without Atopic Dermatitis
Abstract: The epidermis represents an essential barrier versus a broad range of exogenous stimuli. To form a functional epidermis, keratinocytes express filaggrin which plays a vital role in atopic dermatitis. However the relationship between filaggrin and other skin diseases remains unknown. In our study we chose 5 different common skin diseases and analyzed the expression of filaggrin in the skin using immunohistochemistry. Imiquimod (IMQ)-induced mouse model was used for detecting the filaggrin level and barrier function. The results indicated that the expression of filaggrin is reduced in psoriasis compared to the other skin diseases. Furthermore in vivo study showed that the skin barrier is defected with a decreased expression of filaggrin in IMQ-induced psoriasis mouse model, which is accompanied with an increased level of IL-17/IL-23. In conclusion, the defective skin barrier is involved in the development of psoriasis in human and mice with a reduced expression of filaggrin which may be regulated by the increased level of IL-17/IL-23 in the skin.
Cite this paper: Zhang, Y. , Tu, C. , Wang, S. and Xiao, S. (2018) Expression of Skin Barrier Protein Filaggrin in Skin Diseases without Atopic Dermatitis. Journal of Biosciences and Medicines, 6, 101-112. doi: 10.4236/jbm.2018.61009.

[1]   Ross, F.P. and Christiano, A.M. (2006) Nothing but Skin and Bone. Journal of Clinical Investigation, 116, 1140-1149.

[2]   Kubo, A., Nagao, K. and Amagai, M. (2012) Epidermal Barrier Dysfunction and Cutaneous Sensitization in Atopic Diseases. Journal of Clinical Investigation, 122, 440-447.

[3]   Indra, A.K. and Leid, M. (2011) Epidermal Permeability Barrier Measurement in Mammalian Skin. Methods in Molecular Biology, 763, 73-81.

[4]   Schmuth, M., Blunder, S., Dubrac, S., Gruber, R. and Moosbrugger-Martinz, V. (2015) Epidermal Barrier in Hereditary Ichthyoses, Atopic Dermatitis, and Psoriasis. Journal der Deutschen Dermatologischen Gesellschaft, 13, 1119-1123.

[5]   Egawa, G. and Kabashima, K. (2018) Barrier Dysfunction in the Skin Allergy. Allergology International, 67, 3-11.

[6]   Rocha, M.A. and Bagatin, E. (2017) Skin Barrier and Microbiome in Acne. Archives of Dermatological Research, 1-5.

[7]   Chen, H., Ho, J.C., Sandilands, A., Chan, Y.C., Giam, Y.C., Evans, A.T., Lane, E.B. and Mclean, W.H.(2008) Unique and Recurrent Mutations in the Filaggrin Gene in Singaporean Chinese Patients with Ichthyosis Vulgaris. Journal of Investigative Dermatology, 128, 1669-1675.

[8]   Brown, S.J. and Mclean, W.H. (2012) One Remarkable Molecule: Filaggrin. Journal of Investigative Dermatology, 132, 751-762.

[9]   Bowcock, A.M., Shannon, W., Du, F., Duncan, J., Cao, K., Aftergut, K., Catier, J., Fernandez-Vina, M.A. and Menter, A. (2001) Insights into Psoriasis and Other Inflammatory Diseases from Large-Scale Gene Expression Studies. Human Molecular Genetics, 10, 1793-1805.

[10]   Skaaby, T., Husemoen, L.L., Jorgensen, T., Johansen, J.D., Menne, T., Szecsi, P.B., Stender, S., Bager, P., Thyssen, J.P. and Linneberg, A. (2014) Associations of Filaggrin Gene Loss-of-Function Variants and Human Papillomavirus-Related Cancer and Pre-Cancer in Danish Adults. PLoS One, 9, e99437.

[11]   Makino, T., Mizawa, M., Inoue, S., Noguchi, M. and Shimizu, T. (2016) The Expression Profile of Filaggrin-2 in the Normal and Pathologic Human Oral Mucosa. Archives of Dermatological Research, 308, 213-217.

[12]   Swindell, W.R., Michaels, K.A., Sutter, A.J., Diaconu, D., Fritz, Y., Xing, X., Sarkar, M.K., Liang, Y., Tsoi, A., Gudjonsson, J.E. and Ward, N.L. (2017) Imiquimod Has Strain-Dependent Effects in Mice and Does Not Uniquely Model Human Psoriasis. Genome Medicine, 9, 24.

[13]   Dreymueller, D., Martin, C., Kogel, T., Pruessmeyer, J., Hess, F.M., Horiuchi, K., Uhlig, S. and Ludwig, A. (2012) Lung Endothelial ADAM17 Regulates the Acute Inflammatory Response to Lipopolysaccharide. EMBO Molecular Medicine, 4, 412-423.

[14]   Han, H., Thelen, T.D., Comeau, M.R. and Ziegler, S.F. (2014) Thymic Stromal Lymphopoietin-Mediated Epicutaneous Inflammation Promotes Acute Diarrhea and Anaphylaxis. Journal of Clinical Investigation, 124, 5442-5452.

[15]   Howie, N.M., Trigkas, T.K., Cruchley, A.T., Wertz, P.W., Squier, C.A. and Williams, D.M. (2001) Short-Term Exposure to Alcohol Increases the Permeability of Human Oral Mucosa. Oral Diseases, 7, 349-354.

[16]   Mattozzi, C., Paolino, G., Richetta, A.G. and Calvieri, S. (2016) Psoriasis, Vitamin D and the Importance of the Cutaneous Barrier’s Integrity: An Update. The Journal of Dermatology, 43, 507-514.

[17]   Sigmundsdottir, H., Pan, J., Debes, G.F., Alt, C., Habtezion, A., Soler, D. and Butcher, E.C. (2007) DCs Metabolize Sunlight-Induced Vitamin D3 to “Program” T Cell Attraction to the Epidermal Chemokine CCL27. Nature Immunology, 8, 285-293.

[18]   Richetta, A.G., Silvestri, V., Giancristoforo, S., Rizzolo, P., D’epiro, S., Graziano, V., Mattozzi, C., Navazio, A.S., Campoli, M., D’amico, C., Scarno, M., Calvieri, S. and Ottini, L. (2014) A-1012G Promoter Polymorphism of Vitamin D Receptor Gene Is Associated with Psoriasis Risk and Lower Allele-Specific Expression. DNA and Cell Biology, 33, 102-109.

[19]   Denecker, G., Hoste, E., Gilbert, B., Hochepied, T., Ovaere, P., Lippens, S., Van Den Broecke, C., Van Damme, P., D’herde, K., Hachem, J.P., Borgonie, G., Presland, R.B., Schoonjans, L., Libert, C., Vandekerckhove, J., Gevaert, K., Vandenabeele, P. and Declercq, W. (2007) Caspase-14 Protects against Epidermal UVB Photodamage and Water Loss. Nature Cell Biology, 9, 666-674.

[20]   Hvid, M., Johansen, C., Deleuran, B., Kemp, K., Deleuran, M. and Vestergaard, C. (2011) Regulation of Caspase 14 Expression in Keratinocytes by Inflammatory Cytokines—A Possible Link between Reduced Skin Barrier Function and Inflammation? Experimental Dermatology, 20, 633-636.

[21]   Grine, L., Dejager, L., Libert, C. and Vandenbroucke, R.E. (2015) An Inflammatory Triangle in Psoriasis: TNF, Type I IFNs and IL-17. Cytokine & Growth Factor Reviews, 26, 25-33.

[22]   Galluzzo, M., Talamonti, M., D’adamio, S. and Bianchi, L. (2017) Pharmacokinetic Drug Evaluation of Brodalumab for the Treatment of Psoriasis. Expert Opinion on Drug Metabolism & Toxicology, 13, 679-691.

[23]   Donetti, E., Cornaghi, L., Arnaboldi, F., Ricceri, F., Pescitelli, L., Maiocchi, M., Carriero, F., Baruffaldi Preis, F. and Prignano, F. (2017) Epidermal Barrier Reaction to an in Vitro Psoriatic Microenvironment. Experimental Cell Research, 360, 180-188.

[24]   Hanna, E., Abadi, R. and Abbas, O. (2016) Imiquimod in Dermatology: An Overview. International Journal of Dermatology, 55, 831-844.

[25]   Patel, U., Mark, N.M., Machler, B.C. and Levine, V.J. (2011) Imiquimod 5% Cream Induced Psoriasis: A Case Report, Summary of the Literature and Mechanism. British Journal of Dermatology, 164, 670-672.

[26]   Drummond, A., Pichler, J., Argenziano, G., Zalaudek, I., Longo, C., Lallas, A., Piana, S. and Moscarella, E. (2015) Lichen Planopilaris after Imiquimod 5% Cream for Multiple BCC in Basal Cell Naevus Syndrome. Australasian Journal of Dermatology, 56, e105-e107.

[27]   Taylor, C.L., Maslen, M. and Kapembwa, M. (2006) A Case of Severe Eczema Following Use of Imiquimod 5% Cream. Sexually Transmitted Infections, 82, 227-228.

[28]   Cavicchini, S., Vezzoli, P., Muratori, S. and Gianotti, R. (2009) Morbilliform Exanthem Induced by Imiquimod in a Patient with Drug-Related Immunosuppression. Clinical and Experimental Dermatology, 34, 526-527.

[29]   Rabeony, H., Pohin, M., Vasseur, P., Petit-Paris, I., Jegou, J.F., Favot, L., Frouin, E., Boutet, M.A., Blanchard, F., Togbe, D., Ryffel, B., Bernard, F.X., Lecron, J.C. and Morel, F. (2015) IMQ-Induced Skin Inflammation in Mice Is Dependent on IL-1R1 and MyD88 Signaling But Independent of the NLRP3 Inflammasome. European Journal of Immunology, 45, 2847-2857.

[30]   Hanel, K.H., Cornelissen, C., Luscher, B. and Baron, J.M. (2013) Cytokines and the Skin Barrier. International Journal of Molecular Sciences, 14, 6720-6745.

[31]   Hoste, E., Denecker, G., Gilbert, B., Van Nieuwerburgh, F., Van Der Fits, L., Asselbergh, B., De Rycke, R., Hachem, J.P., Deforce, D., Prens, E.P., Vandenabeele, P. and Declercq, W. (2013) Caspase-14-Deficient Mice Are More Prone to the Development of Parakeratosis. Journal of Investigative Dermatology, 133, 742-750.

[32]   Assa, A., Vong, L., Pinnell, L.J., Avitzur, N., Johnson-Henry, K.C. and Sherman, P.M. (2014) Vitamin D Deficiency Promotes Epithelial Barrier Dysfunction and Intestinal Inflammation. The Journal of Infectious Diseases, 210, 1296-1305.

[33]   Wu, S., Liao, A.P., Xia, Y., Li, Y.C., Li, J.D., Sartor, R.B. and Sun, J. (2010) Vitamin D Receptor Negatively Regulates Bacterial-Stimulated NF-kappaB Activity in Intestine. American Journal of Pathology, 177, 686-697.